2026-06-11
Investors
Welcome to Faron’s investor pages!
Faron Pharmaceuticals (AIM: FARN, First North: FARON) is a global, clinical-stage biopharmaceutical company, focused on creating innovative cancer treatments that leverage the patient’s own immune system.
Share price (helsinki)
Share price (london)
19.5 MEUR
R & D expenses in 2023
Over 20 years
Experience in drug development
34
Employees (12/2023)
Latest investor presentation
Please review the latest Faron Pharmaceuticals investor presentation in the accompanying presentation. The presentation covers Faron’s strategy, development pipeline, key strengths, and financials.
Latest releases
faron’s Key strengths
- New and revolutionary therapies for cancer treatment
- Strong scientific base
- A fast-growing target market with limited competition
- Encouraging bexmarilimab Phase I and II Results
- Possibility of future value increase
Quick links
Investor COntacts
